Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin

Figure 4

Survivin is a possible mediator of antitumor synergy between NVP-AEW541 and MK2206, BEZ235, and RAD001. (A) Effects between NVP-AEW541 and MK2206, BEZ235, and RAD001 on survivin expression in HCC cells. HCC cells (Hep3B and Huh7) were treated with NVP-AEW541, MK2206, BEZ235, and RAD001 at the indicated concentrations for 48 hours. Whole-cell lysates were subjected to Western blotting. (B) Survivin knockdown enhanced the efficacy of vertical blockade. Huh7 cells were transfected with si-survivin or scrambled siRNA for 24 hours, and then treated with different drug combination as indicated. (C) Huh7 cells were transfected with V-Survivin (pCMV6-Myc-DKK-survivin) or empty vectors for 8 hours, and then treated with different drug combination as indicated. Whole-cell lysates were collected for Western blotting after 48-hour drug treatment. The percentages of apoptotic cells were measured by flow cytometry after 72-hour drug treatment. Columns, mean of three independent experiments; bars, SD. **, p < 0.01.

Back to article page

Molecular Cancer

ISSN: 1476-4598